| Literature DB >> 30254712 |
Regina Schultz1, Jessica Smith2, Jill M Newby2,3, Tania Gardner1, Christine T Shiner1,4, Gavin Andrews2, Steven G Faux1,4.
Abstract
Objectives: Chronic pain causes significant disability and psychological distress, but barriers often prevent people with pain from engaging in traditional face-to-face pain management programs. Accessible, feasible, and effective alternative treatment options are needed.Entities:
Mesh:
Year: 2018 PMID: 30254712 PMCID: PMC6145162 DOI: 10.1155/2018/9634727
Source DB: PubMed Journal: Pain Res Manag ISSN: 1203-6765 Impact factor: 3.037
Figure 1Participant flow for recruitment and adherence.
Participant demographic and pain characteristics.
| Number (20 in total) | |
|---|---|
| Age | |
| Mean | 47.45 years |
| Range | 24–75 years |
|
| |
| Sex | |
| Male | 1 |
| Female | 19 |
|
| |
| Highest level of education | |
| Postgraduate | 1 |
| Undergraduate | 8 |
| Year 12 | 4 |
| TAFE | 2 |
| Other certificate | 4 |
| No qualification | 1 |
|
| |
| Employment Status | |
| Full time | 3 |
| Part time | 2 |
| Registered sick | 6 |
| Retired | 4 |
| At-home parent | 3 |
| Unemployed | 2 |
|
| |
| Place of residence | |
| Major city | 7 |
| Inner regional area | 3 |
| Outer regional area | 6 |
| Remote area | 4 |
|
| |
| Duration of chronic pain | |
| 1-2 years | 4 |
| 2–5 years | 3 |
| >5 years | 13 |
Estimated marginal means at pre-, mid-, and posttreatment and three months following “Reboot Online.”
| Pretreatment | Midtreatment | Posttreatment | 3-month follow-up | Pre- to posttreatment | Pretreatment to follow-up | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean (SD), | Mean (SD), | Mean (SD), | Mean (SD), |
| Effect size: Hedges | 95% CI |
| Effect size: Hedges | 95% CI | |
| PSEQ | 22.95 (13.77) | 31.80 (13.79) | 36.79 (13.77) | 40.00 (13.77) |
| −1.00 | −1.72 to −0.28 |
| −1.24 | −2.00 to −0.48 |
| BPI-interference | 7.26 (2.06) | 5.27 (2.05) | 4.25 (2.06) | 4.11 (2.06) |
| 1.46 | 0.69–2.23 |
| 1.53 | 0.74 to 2.32 |
| BPI-severity | 5.75 (1.76) | 4.71 (1.75) | 4.27 (1.75) | 3.69 (1.76) |
| 0.84 | 0.13–1.55 |
| 1.17 | 0.42 to 1.92 |
| PCS | 24.50 (8.45) | 19.00 (8.48) | 13.33 (8.19) | 13.55 (8.83) |
| 1.34 | 0.59–2.09 |
| 1.27 | 0.51 to 2.03 |
| TSK | 40.05 (8.90) | 35.47 (8.87) | 34.14 (8.91) | 34.18 (8.89) |
| 0.66 | −0.04–1.36 |
| 0.66 | −0.06 to 1.38 |
| PDI | 43.60 (15.21) | 3.72 (15.22) | 31.21 (15.19) | 27.55 (15.87) |
| 0.82 | 0.11–1.53 |
| 1.03 | 0.29 to 1.77 |
| CPAQ | 51.95 (14.04) | 63.73 (14.02) | 69.50 (14.03) | 70.18 (14.03) |
| −1.25 | −1.99 to −0.51 |
| −1.30 | −2.07 to −0.53 |
| DASS-D | 17.10 (7.92) | 11.87 (7.90) | 8.57 (7.89) | 8.91 (8.24) |
| 1.08 | 0.35–1.81 |
| 1.01 | 0.27 to 1.75 |
| DASS-A | 11.10 (7.74) | 9.47 (7.75) | 6.29 (7.75) | 5.09 (7.75) |
| 0.62 | −0.08–1.32 |
| 0.76 | 0.04 to 1.48 |
| DASS-S | 17.30 (9.21) | 15.73 (9.22) | 12.29 (9.24) | 10.18 (9.63) |
| 0.54 | −0.15–1.23 |
| 0.76 | 0.04 to 1.48 |
| K10 | 26.80 (6.57) | 21.20 (6.58) | 20.50 (6.59) | 19.80 (6.93) |
| 0.96 | 0.24–1.68 |
| 1.04 | 0.30 to 1.78 |
| PHQ-9 | 12.10 (4.70) | 9.40 (4.69) | 8.29 (4.71) | 7.18 (4.92) |
| 0.81 | 0.10–1.52 |
| 1.02 | 0.28 to 1.76 |
p < 0.05; p < 0.01; #p < 0.001.
Figure 2Participant improvement on primary outcome measures. (a) The Pain Self-efficacy Questionnaire (PSEQ), where higher scores indicate greater self-efficacy. (b) The Brief Pain Inventory (BPI)-Interference Score, where lower scores indicate less pain interference. Data are presented as mean and 95% confidence intervals.